<DOC>
	<DOC>NCT01523041</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to compare two formulations of biphasic insulin aspart 70 and characterise the pharmacokinetics of biphasic insulin aspart 50 and biphasic insulin aspart 70 in healthy male subjects.</brief_summary>
	<brief_title>Comparison of Two Formulations of Biphasic Insulin Aspart 70</brief_title>
	<detailed_description>Each subject participated in three treatment periods, and were randomly assigned to each of the six treatment sequences in varying order</detailed_description>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Caucasian Considered generally healthy upon completion of medical history and physical examination as judged by the Investigator Body mass index (BMI) between 1927 kg/m^2 Fasting plasma glucose between 3.86.0 mmol/L Participation in any other clinical trial involving other investigational products within the last three months Clinically significant abnormal haematology or biochemistry screening tests, as judged by the Investigator Any serious systemic infectious disease that occurred in the 4 weeks prior to the first dose of test drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>